265 related articles for article (PubMed ID: 33313384)
21. Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.
Thorn CR; Thomas N; Boyd BJ; Prestidge CA
Drug Deliv Transl Res; 2021 Aug; 11(4):1598-1624. PubMed ID: 33675007
[TBL] [Abstract][Full Text] [Related]
22. Novel Nanotherapeutics as Next-generation Anti-infective Agents: Current Trends and Future Prospectives.
Subhaswaraj P; Syed A; Siddhardha B
Curr Drug Discov Technol; 2020; 17(4):457-468. PubMed ID: 31309893
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.
Munguia J; Nizet V
Trends Pharmacol Sci; 2017 May; 38(5):473-488. PubMed ID: 28283200
[TBL] [Abstract][Full Text] [Related]
24. Technologies to address antimicrobial resistance.
Baker SJ; Payne DJ; Rappuoli R; De Gregorio E
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12887-12895. PubMed ID: 30559181
[TBL] [Abstract][Full Text] [Related]
25. Nanomaterials with active targeting as advanced antimicrobials.
Smerkova K; Dolezelikova K; Bozdechova L; Heger Z; Zurek L; Adam V
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1636. PubMed ID: 32363802
[TBL] [Abstract][Full Text] [Related]
26. Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial pathogens.
Czyż DM; Potluri LP; Jain-Gupta N; Riley SP; Martinez JJ; Steck TL; Crosson S; Shuman HA; Gabay JE
mBio; 2014 Jul; 5(4):e01534-14. PubMed ID: 25073644
[TBL] [Abstract][Full Text] [Related]
27. siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.
Sargazi S; Arshad R; Ghamari R; Rahdar A; Bakhshi A; Karkan SF; Ajalli N; Bilal M; Díez-Pascual AM
Cell Biol Int; 2022 Sep; 46(9):1320-1344. PubMed ID: 35830711
[TBL] [Abstract][Full Text] [Related]
28. Nanomedicine to fight infectious disease.
Rubey KM; Brenner JS
Adv Drug Deliv Rev; 2021 Dec; 179():113996. PubMed ID: 34634395
[TBL] [Abstract][Full Text] [Related]
29. Strategies to prevent the occurrence of resistance against antibiotics by using advanced materials.
Bassegoda A; Ivanova K; Ramon E; Tzanov T
Appl Microbiol Biotechnol; 2018 Mar; 102(5):2075-2089. PubMed ID: 29392390
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticle-based local antimicrobial drug delivery.
Gao W; Chen Y; Zhang Y; Zhang Q; Zhang L
Adv Drug Deliv Rev; 2018 Mar; 127():46-57. PubMed ID: 28939377
[TBL] [Abstract][Full Text] [Related]
31. Expanding the Current Knowledge About the Role of Interleukin-10 to Major Concerning Bacteria.
Peñaloza HF; Noguera LP; Riedel CA; Bueno SM
Front Microbiol; 2018; 9():2047. PubMed ID: 30279680
[TBL] [Abstract][Full Text] [Related]
32. Host-directed drug targeting of factors hijacked by pathogens.
Schwegmann A; Brombacher F
Sci Signal; 2008 Jul; 1(29):re8. PubMed ID: 18648074
[TBL] [Abstract][Full Text] [Related]
33. Nanomaterials-Based Combinatorial Therapy as a Strategy to Combat Antibiotic Resistance.
León-Buitimea A; Garza-Cárdenas CR; Román-García MF; Ramírez-Díaz CA; Ulloa-Ramírez M; Morones-Ramírez JR
Antibiotics (Basel); 2022 Jun; 11(6):. PubMed ID: 35740200
[TBL] [Abstract][Full Text] [Related]
34. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Antimicrobial Resistance Collaborators
Lancet; 2022 Dec; 400(10369):2221-2248. PubMed ID: 36423648
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapies against human bacterial and fungal infectious diseases: A review.
Qadri H; Shah AH; Alkhanani M; Almilaibary A; Mir MA
Front Med (Lausanne); 2023; 10():1135541. PubMed ID: 37122338
[TBL] [Abstract][Full Text] [Related]
36. Intracellular Habitation of
Hommes JW; Surewaard BGJ
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009351
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial peptides´ immune modulation role in intracellular bacterial infection.
Duarte-Mata DI; Salinas-Carmona MC
Front Immunol; 2023; 14():1119574. PubMed ID: 37056758
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial nanomedicine for ocular bacterial and fungal infection.
Fan W; Han H; Chen Y; Zhang X; Gao Y; Li S; Jin Q; Ji J; Yao K
Drug Deliv Transl Res; 2021 Aug; 11(4):1352-1375. PubMed ID: 33840082
[TBL] [Abstract][Full Text] [Related]
39. Nanocarriers for the delivery of antibiotics into cells against intracellular bacterial infection.
Wang C; Yang Y; Cao Y; Liu K; Shi H; Guo X; Liu W; Hao R; Song H; Zhao R
Biomater Sci; 2023 Jan; 11(2):432-444. PubMed ID: 36503914
[TBL] [Abstract][Full Text] [Related]
40. Host Directed Therapy Against Infection by Boosting Innate Immunity.
Bergman P; Raqib R; Rekha RS; Agerberth B; Gudmundsson GH
Front Immunol; 2020; 11():1209. PubMed ID: 32595649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
